Resistencia antimicrobiana de Staphylococcus aislados de la piel de gatos ¿un riesgo para la salud humana?

Actualmente, las patologías dermatológicas son una de las causas deconsulta más frecuentes en la práctica veterinaria de animales pequeños,posiblemente debido a los evidentes signos y lesiones que presentan losanimales: prurito, alopecia y olor desagradable, entre otros.  

Resistencia antimicrobiana de Staphylococcus aislados de la piel de gatos ¿un riesgo para la salud humana?

Actualmente, las patologías dermatológicas son una de las causas deconsulta más frecuentes en la práctica veterinaria de animales pequeños,posiblemente debido a los evidentes signos y lesiones que presentan losanimales: prurito, alopecia y olor desagradable, entre otros.  

In vitro antifungal susceptibility, in vivo antifungal activity and security from a natural product obtained from sunrise oil (AMO 3) against dermatophytes Actividad antifúngica y perfil de seguridad del producto natural derivado del aceite de maravilla o

This work studied safety and antifungal activity of ozonized sunflower oil (AMO 3) against dermatophytes. AMO 3 was prepared through a new original process that modifies the oil before ozonation by alcoholic catalytic esterification. Susceptibility was studied in 41 dermatophytes by agar diffusion and broth microdilution tests. The experimental model to assess the topical safety of the oil included 60 CF1 mice divided in three groups that were treated with vaseline (control), 1% AMO 3 and 50% AMO3 (overdose), respectively. Then, experimental dermatophytosis was induced in CF1 mice. Seventy-five individuals were selected and divided in 5 groups that were treated once a day with placebo, cream with 1%, 2% and 3% AMO 3 plus an untreated control group. This new natural product showed antifungal activity against all strains studied. The MIC ranged between was 0,125 and 1%, while minimum fungicidal concentration (MFC) was 2%. The application of vaseline and AMO 3 1% and 50% did not produce

Detection of the mecA gene in coagulase positive Staphylococcus isolated from cats Detección del gen mecA en cepas de Staphylococcus coagulasa positiva aisladas desde gatos

© 2016, Sociedad Chilena de Infectologia. All rights reserved.Introduction: Bacterial resistance is a global concern for public health. Reports of antimicrobial resistance, including that against methicillin, have increased in strains of coagulase positive Staphylococcus (CPS) isolated from pets, however in Chile this information is limited. Objectives: To determine the antimicrobial susceptibility profiles and to detect the mecA gene in CPS strains isolated from cats in Chile. Materials and Methods: 134 samples were obtained from healthy cats and cats with skin lesions. These strains were characterized in their coagulase production and identified by BBL Crystal kit. The antimicrobial susceptibility was determined by Kirby Bauer method against 12 antimicrobials, including oxacillin. All strains were subjected to PCR to detect the mecA gene. Results: 72 CPS strains were isolated, including S. aureus and S. intermedius. Antimicrobial resistance against at least one drug was detected in

Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ):Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the development and use of novel pharmacological interventions for CHR individuals. We present a description of the participating research networks and the data processing analysis and coordination center, their processes for data harmonization across 43 sites from 13 participating countries (recruitment across North America, Australia, Europe, Asia, and South America), data flow and quality assessment processes, data analyses, and the transfer of data to the National Institute of Mental Health (NIMH) Data Archive (NDA) for use by the research community. In an expected sample of approximately 2000 CHR individuals and 640 matched healthy controls, AMP SCZ will collect clinical, environmental, and cognitive data along with multimodal biomarkers, including neuroimaging, electrophysiology, fluid biospecimens, speech and facial expression samples, novel measures derived from digital health technologies including smartphone-based daily surveys, and passive sensing as well as actigraphy. The study will investigate a range of clinical outcomes over a 2-year period, including transition to psychosis, remission or persistence of CHR status, attenuated positive symptoms, persistent negative symptoms, mood and anxiety symptoms, and psychosocial functioning. The global reach of AMP SCZ and its harmonized innovative methods promise to catalyze the development of new treatments to address critical unmet clinical and public health needs in CHR individuals.</p